Get started
SOPHIA GENETICS SASOPHIA GENETICS SASOPHIA GENETICS SA

SOPHIA GENETICS SA

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

90B chart


Full chart

90B upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪201.81 M‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.98 EUR
Net income (FY)
‪−71.56 M‬ EUR
Revenue (FY)
‪56.51 M‬ EUR
Shares float
‪46.41 M‬
Beta (1Y)
0.47

Employees


Employees (FY)
449
Change (1Y)
−17 −3.65%
Revenue / Employee (1Y)
‪138.91 K‬ EUR
Net income / Employee (1Y)
‪−175.90 K‬ EUR

About SOPHiA GENETICS SA


Sector
Technology Services
Industry
Packaged Software
CEO
Jurgi Camblong
Website
sophiagenetics.com
Headquarters
Rolle
Founded
2011
ISIN
CH1125843347
FIGI
SOPHiA GENETICS SA is a healthcare technology company, which engages in the practice of data driven medicine as the standard of care and for life sciences research. It operates through the following geographical segments: France, Italy, United States, Spain, Turkey, Austria, Brazil, United Kingdom, Switzerland, Germany, and Other. It is the creator of the SOPHiA DDM Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The company was founded by Jurgi Camblong, Pierre Hutter and Lars Steinmetz in 2011 and is headquartered in Saint Sulpice, Switzerland.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

90B news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 90B is 3.02 EUR — it has decreased by −1.29% in the past 24 hours. Watch SOPHIA GENETICS SA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange SOPHIA GENETICS SA stocks are traded under the ticker 90B.
90B stock has fallen by −17.30% compared to the previous week, the month change is a −4.38% fall, over the last year SOPHIA GENETICS SA has showed a −14.69% decrease.
We've gathered analysts' opinions on SOPHIA GENETICS SA future price: according to them, 90B price has a max estimate of 6.47 EUR and a min estimate of 4.62 EUR. Watch 90B chart and read a more detailed SOPHIA GENETICS SA stock forecast: see what analysts think of SOPHIA GENETICS SA and suggest that you do with its stocks.
90B reached its all-time high on Mar 5, 2024 with the price of 5.50 EUR, and its all-time low was 2.76 EUR and was reached on Aug 6, 2024. View more price dynamics on 90B chart.
See other stocks reaching their highest and lowest prices.
90B stock is 1.32% volatile and has beta coefficient of 0.47. Track SOPHIA GENETICS SA stock price on the chart and check out the list of the most volatile stocks — is SOPHIA GENETICS SA there?
Today SOPHIA GENETICS SA has the market capitalization of ‪196.57 M‬, it has decreased by −14.43% over the last week.
Yes, you can track SOPHIA GENETICS SA financials in yearly and quarterly reports right on TradingView.
SOPHIA GENETICS SA is going to release the next earnings report on Mar 11, 2025. Keep track of upcoming events with our Earnings Calendar.
90B earnings for the last quarter are −0.25 EUR per share, whereas the estimation was −0.20 EUR resulting in a −26.13% surprise. The estimated earnings for the next quarter are −0.20 EUR per share. See more details about SOPHIA GENETICS SA earnings.
SOPHIA GENETICS SA revenue for the last quarter amounts to ‪14.24 M‬ EUR, despite the estimated figure of ‪14.24 M‬ EUR. In the next quarter, revenue is expected to reach ‪17.16 M‬ EUR.
90B net income for the last quarter is ‪−16.56 M‬ EUR, while the quarter before that showed ‪−14.18 M‬ EUR of net income which accounts for −16.75% change. Track more SOPHIA GENETICS SA financial stats to get the full picture.
No, 90B doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 449.00 employees. See our rating of the largest employees — is SOPHIA GENETICS SA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SOPHIA GENETICS SA EBITDA is ‪−53.89 M‬ EUR, and current EBITDA margin is −109.94%. See more stats in SOPHIA GENETICS SA financial statements.
Like other stocks, 90B shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SOPHIA GENETICS SA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SOPHIA GENETICS SA technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SOPHIA GENETICS SA stock shows the sell signal. See more of SOPHIA GENETICS SA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.